Literature DB >> 22151063

Serum sclerostin levels were positively correlated with fat mass and bone mineral density in central south Chinese postmenopausal women.

Zhifeng Sheng1, Dejun Tong, Yangna Ou, Hongbin Zhang, Zhimin Zhang, Shuang Li, Jianlin Zhou, Jian Zhang, Eryuan Liao.   

Abstract

OBJECTIVES: To investigate the relationship between serum sclerostin level, body composition, and bone mineral density (BMD) in central south Chinese postmenopausal women.
METHODS: A cross-sectional study was conducted on 260 healthy central southern Chinese postmenopausal women with vs without osteoporosis, aged 50-76 years old. Dual X-ray absorptiometry was used to measure the bone mineral content and BMD of the whole body, lumbar spine and left femur, and total body soft tissue composition. Serum sclerostin levels were measured by a quantitative sandwich enzyme-linked immunosorbent assay.
RESULTS: Compared with women without osteoporosis, osteoporotic women had a significantly lower level of serum sclerostin (P = 0.001). Serum sclerostin levels were positively correlated with body weight, Ponderal index and fat mass. There was a positive correlation with the BMD of both the whole body and at various sites (P < 0.05), even after controlling for age, age at menopause, height and body weight. Multiple linear stepwise regression analysis showed that serum sclerostin level was the most significant determinant of both whole-body and lumbar spine BMD, compared with age, age at menopause, fat mass and lean mass. Age had similar impact as serum sclerostin on hip BMD.
CONCLUSIONS: This study showed that in central south Chinese postmenopausal women, serum sclerostin is lower in women with osteoporosis than without. Serum sclerostin is positively correlated with fat mass and BMD for the whole body, lumbar spine and hip.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22151063     DOI: 10.1111/j.1365-2265.2011.04315.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  36 in total

Review 1.  Novel bone metabolism-associated hormones: the importance of the pre-analytical phase for understanding their physiological roles.

Authors:  Giovanni Lombardi; Mosè Barbaro; Massimo Locatelli; Giuseppe Banfi
Journal:  Endocrine       Date:  2017-02-08       Impact factor: 3.633

Review 2.  The role of osteoblasts in energy homeostasis.

Authors:  Naomi Dirckx; Megan C Moorer; Thomas L Clemens; Ryan C Riddle
Journal:  Nat Rev Endocrinol       Date:  2019-08-28       Impact factor: 43.330

3.  Circulating sclerostin associated with vertebral bone marrow fat in older men but not women.

Authors:  Yu-Heng Vivian Ma; Ann V Schwartz; Sigurdur Sigurdsson; Trisha F Hue; Thomas F Lang; Tamara B Harris; Clifford J Rosen; Eric Vittinghoff; Gudny Eiriksdottir; Alda M Hauksdottir; Kristin Siggeirsdottir; Gunnar Sigurdsson; Diana Oskarsdottir; Nicola Napoli; Lisa Palermo; Vilmundur Gudnason; Xiaojuan Li
Journal:  J Clin Endocrinol Metab       Date:  2014-12       Impact factor: 5.958

4.  Sclerostin serum levels in patients with systemic autoimmune diseases.

Authors:  Concepción Fernández-Roldán; Fernanda Genre; Raquel López-Mejías; Begoña Ubilla; Verónica Mijares; Daniel Sánchez Cano; Concepción López Robles; José Luis Callejas-Rubio; Raquel Ríos Fernández; Manuela Expósito Ruiz; Miguel Á González-Gay; Norberto Ortego Centeno
Journal:  Bonekey Rep       Date:  2016-02-03

5.  Sclerostin influences body composition by regulating catabolic and anabolic metabolism in adipocytes.

Authors:  Soohyun P Kim; Julie L Frey; Zhu Li; Priyanka Kushwaha; Meredith L Zoch; Ryan E Tomlinson; Hao Da; Susan Aja; Hye Lim Noh; Jason K Kim; Mehboob A Hussain; Daniel L J Thorek; Michael J Wolfgang; Ryan C Riddle
Journal:  Proc Natl Acad Sci U S A       Date:  2017-12-11       Impact factor: 11.205

6.  Connecting Bone and Fat: The Potential Role for Sclerostin.

Authors:  Heather Fairfield; Clifford J Rosen; Michaela R Reagan
Journal:  Curr Mol Biol Rep       Date:  2017-04-18

7.  Serum sclerostin: the missing link in the bone-vessel cross-talk in hemodialysis patients?

Authors:  S Pelletier; C B Confavreux; J Haesebaert; F Guebre-Egziabher; J Bacchetta; M-C Carlier; L Chardon; M Laville; R Chapurlat; G M London; M-H Lafage-Proust; D Fouque
Journal:  Osteoporos Int       Date:  2015-04-25       Impact factor: 4.507

8.  Serum sclerostin levels in healthy men over 50 years of age.

Authors:  Harjit Pal Bhattoa; John Wamwaki; Edit Kalina; Roza Foldesi; Adam Balogh; Peter Antal-Szalmas
Journal:  J Bone Miner Metab       Date:  2013-03-24       Impact factor: 2.626

9.  Osteocyte-Secreted Wnt Signaling Inhibitor Sclerostin Contributes to Beige Adipogenesis in Peripheral Fat Depots.

Authors:  Keertik Fulzele; Forest Lai; Christopher Dedic; Vaibhav Saini; Yuhei Uda; Chao Shi; Padrig Tuck; Jenna L Aronson; Xiaolong Liu; Jordan M Spatz; Marc N Wein; Paola Divieti Pajevic
Journal:  J Bone Miner Res       Date:  2017-01-05       Impact factor: 6.741

10.  Effect of Qing'e formula on circulating sclerostin levels in patients with postmenopausal osteoporosis.

Authors:  Yan-Ping Yang; Bo Shuai; Lin Shen; Xiao-Juan Xu; Chen Ma; Lin Lv
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.